GlassScriptPhysician profile
Asefa K Gebre
NPI 1700245628
$3,011.67
in general payments reported to CMS, 2019-2025
29 companies · $698 in 2025
The $698 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $574 · 2022: $554 · 2023: $651 · 2024: $535 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,747 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,747.01 |
| Education | $137.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $763.71 | 2021-2025 | |
| Lilly USA, LLC | $237.04 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $229.20 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $211.72 | 2021-2025 | Fanapt, Hetlioz |
| Novo Nordisk INC | $168.68 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $165.47 | 2025 | Caplyta |
| Medical Device Business Services, INC. | $137.01 | 2023 | Dermabond |
| Exact Sciences Corporation | $118.34 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lundbeck LLC | $116.97 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $108.37 | 2022-2025 | Farxiga, Breztri |
| Globus Medical, INC. | $97.71 | 2025 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.12 | 2022-2024 | Xifaxan |
| Collegium Pharmaceutical, INC. | $80.96 | 2021 | |
| Indivior INC. | $76.18 | 2022-2023 | Sublocade |
| Mylan Specialty L.P. | $65.50 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apria Healthcare LLC | $52.56 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.56 | 2021-2023 | Jardiance |
| Amgen INC. | $34.43 | 2023 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $33.36 | 2021 | |
| Ardelyx, INC. | $27.58 | 2024 | Ibsrela |
| Braeburn INC. | $21.11 | 2023 | Brixadi |
| Verona Pharma, INC. | $19.31 | 2025 | Ohtuvayre |
| Edwards Lifesciences Corporation | $17.80 | 2022 | |
| Pfizer INC. | $17.32 | 2021 | |
| Dexcom, INC. | $16.36 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.86 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.23 | 2025 | Spravato |
| Philips North America LLC | $11.89 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asefa Gebre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.